Quick Answer
TREACE MEDICAL CONCEPTS, INC. reported Net Income Loss of -$59.00 million for the year ending 2025.
- TREACE MEDICAL CONCEPTS, INC. showed a decrease of -5.8% in Net Income Loss from 2024 to 2025.
- This data is from TREACE MEDICAL CONCEPTS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.61 million | Q2 2020: -$1.97 million | Q3 2020: -$2.66 million | Q1 2021: -$2.43 million | Q2 2021: -$5.08 million | Q3 2021: -$6.42 million | Q1 2022: -$9.04 million | Q2 2022: -$17.23 million | Q3 2022: -$12.13 million | Q1 2023: -$13.45 million | Q2 2023: -$12.27 million | Q3 2023: -$17.52 million | Q1 2024: -$18.68 million | Q2 2024: -$21.21 million | Q3 2024: -$15.36 million | Q1 2025: -$15.92 million | Q2 2025: -$17.40 million | Q3 2025: -$16.29 million.
- Over the full 7 years of available data (2019 to 2025), TREACE MEDICAL CONCEPTS, INC.'s Net Income Loss has declined by 1,283.4%.
- Historical annual values: Fiscal year 2025: -$59.00 million | Fiscal year 2024: -$55.74 million | Fiscal year 2023: -$49.53 million | Fiscal year 2022: -$42.82 million | Fiscal year 2021: -$20.55 million | Fiscal year 2020: -$3.67 million | Fiscal year 2019: -$4.27 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: